Logo image of MTSR

METSERA INC (MTSR) Stock Fundamental Analysis

NASDAQ:MTSR - Nasdaq - US59267L1070 - Common Stock - Currency: USD

22.15  -1.83 (-7.63%)

Fundamental Rating

3

MTSR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 563 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MTSR as it has an excellent financial health rating, but there are worries on the profitability. MTSR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MTSR has reported negative net income.
In the past year MTSR has reported a negative cash flow from operations.
MTSR Yearly Net Income VS EBIT VS OCF VS FCFMTSR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

MTSR has a Return On Assets (-46.37%) which is in line with its industry peers.
MTSR has a Return On Equity of -72.78%. This is comparable to the rest of the industry: MTSR outperforms 54.17% of its industry peers.
Industry RankSector Rank
ROA -46.37%
ROE -72.78%
ROIC N/A
ROA(3y)-26.59%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MTSR Yearly ROA, ROE, ROICMTSR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 50 -50

1.3 Margins

MTSR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTSR Yearly Profit, Operating, Gross MarginsMTSR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, MTSR has about the same amount of shares outstanding.
MTSR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MTSR Yearly Shares OutstandingMTSR Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 20M 40M 60M 80M 100M
MTSR Yearly Total Debt VS Total AssetsMTSR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

MTSR has an Altman-Z score of 7.57. This indicates that MTSR is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of MTSR (7.57) is better than 84.55% of its industry peers.
There is no outstanding debt for MTSR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.57
ROIC/WACCN/A
WACCN/A
MTSR Yearly LT Debt VS Equity VS FCFMTSR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

MTSR has a Current Ratio of 5.34. This indicates that MTSR is financially healthy and has no problem in meeting its short term obligations.
MTSR has a Current ratio of 5.34. This is comparable to the rest of the industry: MTSR outperforms 58.08% of its industry peers.
A Quick Ratio of 5.34 indicates that MTSR has no problem at all paying its short term obligations.
The Quick ratio of MTSR (5.34) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.34
Quick Ratio 5.34
MTSR Yearly Current Assets VS Current LiabilitesMTSR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for MTSR have decreased strongly by -342.97% in the last year.
EPS 1Y (TTM)-342.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-305.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MTSR is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -13.43% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-5.78%
EPS Next 2Y-6.14%
EPS Next 3Y-13.43%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MTSR Yearly EPS VS EstimatesMTSR Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MTSR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MTSR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MTSR Price Earnings VS Forward Price EarningsMTSR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MTSR Per share dataMTSR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A cheap valuation may be justified as MTSR's earnings are expected to decrease with -13.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.14%
EPS Next 3Y-13.43%

More info and screens

0

5. Dividend

5.1 Amount

MTSR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

METSERA INC

NASDAQ:MTSR (5/6/2025, 12:44:39 PM)

22.15

-1.83 (-7.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26 2025-03-26/bmo
Earnings (Next)N/A N/A
Inst Owners38.56%
Inst Owner ChangeN/A
Ins Owners0.93%
Ins Owner Change11.92%
Market Cap2.33B
Analysts86.67
Price Target47.94 (116.43%)
Short Float %8.22%
Short Ratio8.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16.07%
PT rev (3m)N/A
EPS NQ rev (1m)1.92%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-4.8%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.1
P/tB 11.82
EV/EBITDA N/A
EPS(TTM)-2.03
EYN/A
EPS(NY)-3.45
Fwd EYN/A
FCF(TTM)-0.95
FCFYN/A
OCF(TTM)-0.95
OCFYN/A
SpS0
BVpS2.74
TBVpS1.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.37%
ROE -72.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.59%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 307.14%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.34
Quick Ratio 5.34
Altman-Z 7.57
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-342.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-305.61%
EPS Next Y-5.78%
EPS Next 2Y-6.14%
EPS Next 3Y-13.43%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-571.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-134.22%
EBIT Next 3Y-53.78%
EBIT Next 5YN/A
FCF growth 1Y-182.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-182.65%
OCF growth 3YN/A
OCF growth 5YN/A